ADC Therapeutics (ADCT) Gross Profit (2023 - 2026)

ADC Therapeutics' (ADCT) quarterly Gross Profit came in at $7.3 million in Q1 2026, up 231.91% year-on-year from $2.2 million in Q1 2025, and up 44.71% quarter-over-quarter from $5.1 million in Q3 2025.

ADC Therapeutics (ADCT) Gross Profit (2023 - 2026) Analysis & Trends

ADC Therapeutics has disclosed Gross Profit across 4 years of filings, most recently posting $7.3 million for Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Alterity Therapeutics 762,369.55 Bn 762,369.51 Bn -
2 Belite Bio 55,096.00 Bn 55,096.00 Bn -
3 Quantum Biopharma 17,755.80 Bn 17,755.79 Bn -
4 Legend Biotech 3,486.00 Bn 3,485.71 Bn 242.10 Mn
5 Akari Therapeutics 1,737.42 Bn 1,737.41 Bn -
6 Evaxion A 1,551.28 Bn 1,551.26 Bn -
7 Psyence Biomedical 227.32 Bn 227.31 Bn -
8 Vertex Pharmaceuticals 110.84 Bn 103.59 Bn 2.59 Bn
9 Abivax 91.71 Bn 91.71 Bn -
10 ADC Therapeutics 167.24 Mn -63.76 Mn 7.33 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 7.33 Mn
Mar 31, 2026 7.33 Mn
Sep 30, 2025 5.06 Mn
Sep 30, 2025 5.06 Mn
Jun 30, 2025 8.69 Mn
Jun 30, 2025 8.69 Mn
Mar 31, 2025 -5.55 Mn
Mar 31, 2025 -5.55 Mn
Sep 30, 2024 7.34 Mn
Sep 30, 2024 7.34 Mn
Jun 30, 2024 6.33 Mn
Jun 30, 2024 6.33 Mn
Mar 31, 2024 6.66 Mn
Mar 31, 2024 6.66 Mn
Sep 30, 2023 763,000.00
Sep 30, 2023 763,000.00
Jun 30, 2023 4.83 Mn
Jun 30, 2023 4.83 Mn